NASDAQ
No price data available for this timeframe.
Apogee Therapeutics, Inc. (APGE) has had 25 insider transactions recently, with net insider activity of -$63K (net selling). The most active insider is Fairmount Funds Management LLC (Director).
Total Transactions
25
4 buys /21 sells
Shares Acquired
15,375
Transactions: 4•Avg: 3,843.75
Shares Disposed
77,875
Transactions: 21•Avg: 3,708.33
Net Activity
-62,500
Net Selling•Ratio: 19.05%
Q2 2026(Current) | 15,375 | 77,875 | -62,500 | 19.05% |
Q1 2026 | 442,671 | 1,875,975 | -1,433,304 | 15.38% |
Q4 2025 | 376,298 | 124,740 | +251,558 | 14.29% |
Q3 2025 | 7,365 | 22,905 | -15,540 | 14.29% |
Q2 2025 | 101,227 | 9,310 | +91,917 | 140.00% |
This table shows insider trading activity by quarter. A ratio > 100% indicates insiders acquired more shares than they disposed of during the period, which is generally considered a bullish signal.
• Most recent data for Q2 2026
Acquired vs Disposed Shares
Net Distribution: 62,500 shares•Acquired/Disposed Ratio: 19.05%
Net Activity | |||||
|---|---|---|---|---|---|
FFML Fairmount Funds Management LLC | Director | 1 | 0 | 1,750,000 | -1,750,000 |
SNP Shah Nimish P | Director | 1 | 365,853 | 0 | +365,853 |
HMT HENDERSON MICHAEL THOMAS | Director, officer: chief executive officer | 28 | 256,016 | 183,000 | +73,016 |
HJ Henderson Jane | Officer: chief financial officer | 23 | 83,690 | 27,500 | +56,190 |
DC Dambkowski Carl | Officer: chief medical officer | 47 | 136,150 | 132,884 | +3,266 |
This table shows the trading activity of the most active company insiders. Positive net activity (buying more than selling) is often considered a bullish signal.
2026-06-03 | Officer: chief medical officer | Purchase | 4,125 | $22.86 | $94,297.5 | 211,148 | |
2026-06-03 | Officer: chief medical officer | Sale | 5,500 | $78.71 | $432,905 | 205,648 | |
2026-06-03 | Officer: chief medical officer | Sale | 4,125 | $22.86 | $94,297.5 | 118,915 | |
2026-05-13 | Director, officer: chief executive officer | Sale | 18,659 | $82.05 | $1,530,970.95 | 1,117,328 | |
2026-05-13 | Director, officer: chief executive officer | Sale | 1,341 | $82.58 | $110,739.78 | 1,115,987 |
This table displays recent Form 4 filings showing transactions by company insiders. SEC rules require insiders to report their transactions within two business days.
DC Dambkowski Carl | Officer: chief medical officer | Jun 5, 2026 | |
DC Dambkowski Carl | Officer: chief medical officer | Jun 5, 2026 | |
DC Dambkowski Carl | Officer: chief medical officer | Jun 5, 2026 | |
HMT HENDERSON MICHAEL THOMAS | Director, officer: chief executive officer | May 15, 2026 | |
HMT HENDERSON MICHAEL THOMAS | Director, officer: chief executive officer | May 15, 2026 |
Net change in shares shown on right